molecules of the month

Remogliflozin etabonate

SGLT1-sparing oral SGLT2 inhibitor prodrug

launched in India for diabetes, 100 mg BID

from mouse urine drug metabolite and opt.

Bioorg. Med. Chem., Jan. 22, 2021

Kissei Pharma / Toho University, JP

1 min read

The Kissei SGLT2 inhibitor prodrug, remogliflozin etabonate, is an SGLT1-sparing oral drug launched in 2019 in India for the treatment of type 2 diabetes.  Interestingly, the lead for this drug was a metabolite identified from mouse urine after treatment with a Wyeth-Ayerst antihyperglycemic agent of previously unknown mechanism. 

request a trial

Drug Hunter is commited to helping industry innovators make informed decisions. Premium members have access to our library of the latest stories in science, written by scientists.

Request a trial to access insights powering the pros in our industry.

already a member? log in: